News
Extrapolation of indications in biosimilars: filgrastim
2015-08-03 Extrapolation* of indications for biosimilars is a contentious issue and has been met with concern by physicians. Members of the European Medicines Agency’s (EMA) Biosimilar… Read More »
Biosimilars use in Europe varies widely
2015-07-30 Use of biosimilars in Europe varies widely between countries and therapy areas, according to a report published by IMS Health in October 2014. Biologicals currently… Read More »
Biosimilars: when indications can be extrapolated
2015-07-28 Extrapolation* is already a well-established and accepted scientific and regulatory principle, according to members of the European Medicines Agency’s (EMA) Biosimilar Medicinal Products Working Party… Read More »
Development of biosimilars for rheumatoid arthritis
2015-07-24 Biosimilars development is a hive of activity, with development of biosimilars for the treatment of rheumatoid arthritis being one of the busiest areas in the… Read More »
Predicting the response of diabetes patients to biosimilar insulin
2015-07-22 For patients with type 1 diabetes, the quality of the insulin they take is a matter of life and death. The situation is similar for… Read More »
Biosimilars: similar but not identical
2015-07-20 One reason for distrust among physicians over using biosimilars in extrapolated* indications could be the fact that it is frequently cited that biosimilars are ‘similar… Read More »
Study results show safety of switching to biosimilar infliximab
2015-07-16 US-based Epirus Biopharmaceuticals (Epirus) announced on 23 September 2014 positive week 58 follow-up data from its global phase III study for its biosimilar infliximab (BOW015).… Read More »
Patients satisfied with generics
2015-07-14 A report by health information resource, Iodine, has found that patients have a similar level of satisfaction with generics compared to brand-name drugs. The study… Read More »
Improved labelling sought for biosimilar acceptance
2015-07-10 The terms of approval for every biosimilar and its reference product must be made clearer, argue the European Biopharmaceutical Enterprises (EBE) [1]. The development of… Read More »
Generics save US 1.5 trillion over last 10 years
2015-07-08 Generics have saved consumers and the US healthcare system US$239 billion in 2013 and have saved the US nearly US$1.5 trillion between 2004 and 2013,… Read More »
